Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization
BACKGROUND: Neuropeptide Y is a sympathetic neurotransmitter, a potent endothelium-derived angiogenic factor and a vascular mitogen. We have studied the role of the functional leucine7 to proline7 polymorphism of the signal peptide region of preproneuropeptide Y (prepro-NPY) as a genetic susceptibil...
Gespeichert in:
| Veröffentlicht in: | Annals of medicine (Helsinki) 2004, Vol.36 (3), p.232-240 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 240 |
|---|---|
| container_issue | 3 |
| container_start_page | 232 |
| container_title | Annals of medicine (Helsinki) |
| container_volume | 36 |
| creator | Koulu, Markku Movafagh, Sharareh Tuohimaa, Jukka Jaakkola, Ulriikka Kallio, Jaana Pesonen, Ullamari Geng, Yixun Karvonen, Matti K Vainio-Jylhä, Elina Pöllönen, Matti Kaipio-Salmi, Katja Seppälä, Helena Lee, Edward W Higgins, Rosemary D Zukowska, Zofia |
| description | BACKGROUND: Neuropeptide Y is a sympathetic neurotransmitter, a potent endothelium-derived angiogenic factor and a vascular mitogen. We have studied the role of the functional leucine7 to proline7 polymorphism of the signal peptide region of preproneuropeptide Y (prepro-NPY) as a genetic susceptibility factor for diabetic retinopathy. In addition, we investigated the role of the NPY Y2-receptor as a putative mediator of angiogenic NPY signaling in the retina.
METHODS: Frequencies of proline7 (Pro7) carriers in the prepro-NPY were determined in type 1 and type 2 diabetes patients having retinopathy, in type 2 diabetes patients without retinopathy and in healthy control subjects. The role of Y2-receptor in hyperoxemia-induced retinal neovascularization was investigated in Y2-receptor knockout mice (Y2
− −
) and in rats administered Y2-receptor mRNA antisense oligonucleotide.
RESULTS: The carriers having Pro7 in the preproNPY are markedly over-represented among type 2 diabetes patients with retinopathy compared to type 2 diabetes patients without retinopathy and to the population control. Neonatal exposure to hyperoxia resulted in development of retinal neovascularization that was prevented in Y2
− −
-mice, and significantly inhibited in rats treated with the Y2-receptor antisense oligonucleotide.
CONCLUSIONS: NPY and Y2-receptor play important roles in diabetic retinopathy and retinal neovascularization and are thus potential new targets for drug molecules for treatment of retinopathy. |
| doi_str_mv | 10.1080/07853890410031236 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_15710234</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71994703</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-4a0535670bf6f1dc4c648b5e0901da9a7e41fd3f82784fea03e11075f1a032a33</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi1ERZfCD-CCfIFb6DhO4kRwqSq-pKpc4NBTNGuPta6cOLWTRcuvx9tdBKhSL_aM_byjmXcYeyXgnYAWzkG1tWw7qASAFKVsnrCVkE1dlNDAU7ba_xd74JQ9T-kWAEol4Bk7FbVoRae6Fbu7piWGiabZGeI3HEfDb8oiks5PIXKMxN24DX5LJgfc0JZ8mAYaZx4sNw7XNDvNYz7HMOG82d3XuM_R85HCFpNePEb3C2cXxhfsxKJP9PJ4n7Efnz5-v_xSXH37_PXy4qrQlSznokKoZd0oWNvGCqMr3VTtuiboQBjsUFElrJG2LVVbWUKQJASo2ooclijlGXt7qDvFcLdQmvvBJU3eY-5pSb0SXVcp2IPiAOoYUopk-ym6AeOuF9Dvfe4f-Jw1r4_Fl_VA5q_iaGwG3hyBPD16G3HULv3D5UWUssrchwPnRhvigD9D9KafcedD_COSj_Xx_j_5htDPG5231t-GJeYNpEem-A0kkKvF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71994703</pqid></control><display><type>article</type><title>Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization</title><source>Taylor & Francis:Master (3349 titles)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Koulu, Markku ; Movafagh, Sharareh ; Tuohimaa, Jukka ; Jaakkola, Ulriikka ; Kallio, Jaana ; Pesonen, Ullamari ; Geng, Yixun ; Karvonen, Matti K ; Vainio-Jylhä, Elina ; Pöllönen, Matti ; Kaipio-Salmi, Katja ; Seppälä, Helena ; Lee, Edward W ; Higgins, Rosemary D ; Zukowska, Zofia</creator><creatorcontrib>Koulu, Markku ; Movafagh, Sharareh ; Tuohimaa, Jukka ; Jaakkola, Ulriikka ; Kallio, Jaana ; Pesonen, Ullamari ; Geng, Yixun ; Karvonen, Matti K ; Vainio-Jylhä, Elina ; Pöllönen, Matti ; Kaipio-Salmi, Katja ; Seppälä, Helena ; Lee, Edward W ; Higgins, Rosemary D ; Zukowska, Zofia</creatorcontrib><description>BACKGROUND: Neuropeptide Y is a sympathetic neurotransmitter, a potent endothelium-derived angiogenic factor and a vascular mitogen. We have studied the role of the functional leucine7 to proline7 polymorphism of the signal peptide region of preproneuropeptide Y (prepro-NPY) as a genetic susceptibility factor for diabetic retinopathy. In addition, we investigated the role of the NPY Y2-receptor as a putative mediator of angiogenic NPY signaling in the retina.
METHODS: Frequencies of proline7 (Pro7) carriers in the prepro-NPY were determined in type 1 and type 2 diabetes patients having retinopathy, in type 2 diabetes patients without retinopathy and in healthy control subjects. The role of Y2-receptor in hyperoxemia-induced retinal neovascularization was investigated in Y2-receptor knockout mice (Y2
− −
) and in rats administered Y2-receptor mRNA antisense oligonucleotide.
RESULTS: The carriers having Pro7 in the preproNPY are markedly over-represented among type 2 diabetes patients with retinopathy compared to type 2 diabetes patients without retinopathy and to the population control. Neonatal exposure to hyperoxia resulted in development of retinal neovascularization that was prevented in Y2
− −
-mice, and significantly inhibited in rats treated with the Y2-receptor antisense oligonucleotide.
CONCLUSIONS: NPY and Y2-receptor play important roles in diabetic retinopathy and retinal neovascularization and are thus potential new targets for drug molecules for treatment of retinopathy.</description><identifier>ISSN: 0785-3890</identifier><identifier>EISSN: 1365-2060</identifier><identifier>DOI: 10.1080/07853890410031236</identifier><identifier>PMID: 15181979</identifier><language>eng</language><publisher>Basingstoke: Informa UK Ltd</publisher><subject>Adult ; Aged ; Animals ; Biological and medical sciences ; Diabetes Mellitus, Type 1 - complications ; Diabetes Mellitus, Type 2 - complications ; Diabetic Retinopathy - etiology ; Female ; General aspects ; Humans ; Male ; Medical sciences ; Mice ; Middle Aged ; neuropeptide Y ; Neuropeptide Y - physiology ; Ophthalmology ; Rats ; Receptors, Neuropeptide Y - physiology ; Retinal Neovascularization - etiology ; Retinopathies ; retinopathy ; Y2-receptor</subject><ispartof>Annals of medicine (Helsinki), 2004, Vol.36 (3), p.232-240</ispartof><rights>2004 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2004</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-4a0535670bf6f1dc4c648b5e0901da9a7e41fd3f82784fea03e11075f1a032a33</citedby><cites>FETCH-LOGICAL-c432t-4a0535670bf6f1dc4c648b5e0901da9a7e41fd3f82784fea03e11075f1a032a33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/07853890410031236$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/07853890410031236$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,776,780,4010,27900,27901,27902,59620,60409,61194,61375</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15710234$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15181979$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koulu, Markku</creatorcontrib><creatorcontrib>Movafagh, Sharareh</creatorcontrib><creatorcontrib>Tuohimaa, Jukka</creatorcontrib><creatorcontrib>Jaakkola, Ulriikka</creatorcontrib><creatorcontrib>Kallio, Jaana</creatorcontrib><creatorcontrib>Pesonen, Ullamari</creatorcontrib><creatorcontrib>Geng, Yixun</creatorcontrib><creatorcontrib>Karvonen, Matti K</creatorcontrib><creatorcontrib>Vainio-Jylhä, Elina</creatorcontrib><creatorcontrib>Pöllönen, Matti</creatorcontrib><creatorcontrib>Kaipio-Salmi, Katja</creatorcontrib><creatorcontrib>Seppälä, Helena</creatorcontrib><creatorcontrib>Lee, Edward W</creatorcontrib><creatorcontrib>Higgins, Rosemary D</creatorcontrib><creatorcontrib>Zukowska, Zofia</creatorcontrib><title>Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization</title><title>Annals of medicine (Helsinki)</title><addtitle>Ann Med</addtitle><description>BACKGROUND: Neuropeptide Y is a sympathetic neurotransmitter, a potent endothelium-derived angiogenic factor and a vascular mitogen. We have studied the role of the functional leucine7 to proline7 polymorphism of the signal peptide region of preproneuropeptide Y (prepro-NPY) as a genetic susceptibility factor for diabetic retinopathy. In addition, we investigated the role of the NPY Y2-receptor as a putative mediator of angiogenic NPY signaling in the retina.
METHODS: Frequencies of proline7 (Pro7) carriers in the prepro-NPY were determined in type 1 and type 2 diabetes patients having retinopathy, in type 2 diabetes patients without retinopathy and in healthy control subjects. The role of Y2-receptor in hyperoxemia-induced retinal neovascularization was investigated in Y2-receptor knockout mice (Y2
− −
) and in rats administered Y2-receptor mRNA antisense oligonucleotide.
RESULTS: The carriers having Pro7 in the preproNPY are markedly over-represented among type 2 diabetes patients with retinopathy compared to type 2 diabetes patients without retinopathy and to the population control. Neonatal exposure to hyperoxia resulted in development of retinal neovascularization that was prevented in Y2
− −
-mice, and significantly inhibited in rats treated with the Y2-receptor antisense oligonucleotide.
CONCLUSIONS: NPY and Y2-receptor play important roles in diabetic retinopathy and retinal neovascularization and are thus potential new targets for drug molecules for treatment of retinopathy.</description><subject>Adult</subject><subject>Aged</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Diabetes Mellitus, Type 1 - complications</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetic Retinopathy - etiology</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Middle Aged</subject><subject>neuropeptide Y</subject><subject>Neuropeptide Y - physiology</subject><subject>Ophthalmology</subject><subject>Rats</subject><subject>Receptors, Neuropeptide Y - physiology</subject><subject>Retinal Neovascularization - etiology</subject><subject>Retinopathies</subject><subject>retinopathy</subject><subject>Y2-receptor</subject><issn>0785-3890</issn><issn>1365-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v1DAQhi1ERZfCD-CCfIFb6DhO4kRwqSq-pKpc4NBTNGuPta6cOLWTRcuvx9tdBKhSL_aM_byjmXcYeyXgnYAWzkG1tWw7qASAFKVsnrCVkE1dlNDAU7ba_xd74JQ9T-kWAEol4Bk7FbVoRae6Fbu7piWGiabZGeI3HEfDb8oiks5PIXKMxN24DX5LJgfc0JZ8mAYaZx4sNw7XNDvNYz7HMOG82d3XuM_R85HCFpNePEb3C2cXxhfsxKJP9PJ4n7Efnz5-v_xSXH37_PXy4qrQlSznokKoZd0oWNvGCqMr3VTtuiboQBjsUFElrJG2LVVbWUKQJASo2ooclijlGXt7qDvFcLdQmvvBJU3eY-5pSb0SXVcp2IPiAOoYUopk-ym6AeOuF9Dvfe4f-Jw1r4_Fl_VA5q_iaGwG3hyBPD16G3HULv3D5UWUssrchwPnRhvigD9D9KafcedD_COSj_Xx_j_5htDPG5231t-GJeYNpEem-A0kkKvF</recordid><startdate>2004</startdate><enddate>2004</enddate><creator>Koulu, Markku</creator><creator>Movafagh, Sharareh</creator><creator>Tuohimaa, Jukka</creator><creator>Jaakkola, Ulriikka</creator><creator>Kallio, Jaana</creator><creator>Pesonen, Ullamari</creator><creator>Geng, Yixun</creator><creator>Karvonen, Matti K</creator><creator>Vainio-Jylhä, Elina</creator><creator>Pöllönen, Matti</creator><creator>Kaipio-Salmi, Katja</creator><creator>Seppälä, Helena</creator><creator>Lee, Edward W</creator><creator>Higgins, Rosemary D</creator><creator>Zukowska, Zofia</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2004</creationdate><title>Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization</title><author>Koulu, Markku ; Movafagh, Sharareh ; Tuohimaa, Jukka ; Jaakkola, Ulriikka ; Kallio, Jaana ; Pesonen, Ullamari ; Geng, Yixun ; Karvonen, Matti K ; Vainio-Jylhä, Elina ; Pöllönen, Matti ; Kaipio-Salmi, Katja ; Seppälä, Helena ; Lee, Edward W ; Higgins, Rosemary D ; Zukowska, Zofia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-4a0535670bf6f1dc4c648b5e0901da9a7e41fd3f82784fea03e11075f1a032a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Diabetes Mellitus, Type 1 - complications</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetic Retinopathy - etiology</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Middle Aged</topic><topic>neuropeptide Y</topic><topic>Neuropeptide Y - physiology</topic><topic>Ophthalmology</topic><topic>Rats</topic><topic>Receptors, Neuropeptide Y - physiology</topic><topic>Retinal Neovascularization - etiology</topic><topic>Retinopathies</topic><topic>retinopathy</topic><topic>Y2-receptor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koulu, Markku</creatorcontrib><creatorcontrib>Movafagh, Sharareh</creatorcontrib><creatorcontrib>Tuohimaa, Jukka</creatorcontrib><creatorcontrib>Jaakkola, Ulriikka</creatorcontrib><creatorcontrib>Kallio, Jaana</creatorcontrib><creatorcontrib>Pesonen, Ullamari</creatorcontrib><creatorcontrib>Geng, Yixun</creatorcontrib><creatorcontrib>Karvonen, Matti K</creatorcontrib><creatorcontrib>Vainio-Jylhä, Elina</creatorcontrib><creatorcontrib>Pöllönen, Matti</creatorcontrib><creatorcontrib>Kaipio-Salmi, Katja</creatorcontrib><creatorcontrib>Seppälä, Helena</creatorcontrib><creatorcontrib>Lee, Edward W</creatorcontrib><creatorcontrib>Higgins, Rosemary D</creatorcontrib><creatorcontrib>Zukowska, Zofia</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of medicine (Helsinki)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koulu, Markku</au><au>Movafagh, Sharareh</au><au>Tuohimaa, Jukka</au><au>Jaakkola, Ulriikka</au><au>Kallio, Jaana</au><au>Pesonen, Ullamari</au><au>Geng, Yixun</au><au>Karvonen, Matti K</au><au>Vainio-Jylhä, Elina</au><au>Pöllönen, Matti</au><au>Kaipio-Salmi, Katja</au><au>Seppälä, Helena</au><au>Lee, Edward W</au><au>Higgins, Rosemary D</au><au>Zukowska, Zofia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization</atitle><jtitle>Annals of medicine (Helsinki)</jtitle><addtitle>Ann Med</addtitle><date>2004</date><risdate>2004</risdate><volume>36</volume><issue>3</issue><spage>232</spage><epage>240</epage><pages>232-240</pages><issn>0785-3890</issn><eissn>1365-2060</eissn><abstract>BACKGROUND: Neuropeptide Y is a sympathetic neurotransmitter, a potent endothelium-derived angiogenic factor and a vascular mitogen. We have studied the role of the functional leucine7 to proline7 polymorphism of the signal peptide region of preproneuropeptide Y (prepro-NPY) as a genetic susceptibility factor for diabetic retinopathy. In addition, we investigated the role of the NPY Y2-receptor as a putative mediator of angiogenic NPY signaling in the retina.
METHODS: Frequencies of proline7 (Pro7) carriers in the prepro-NPY were determined in type 1 and type 2 diabetes patients having retinopathy, in type 2 diabetes patients without retinopathy and in healthy control subjects. The role of Y2-receptor in hyperoxemia-induced retinal neovascularization was investigated in Y2-receptor knockout mice (Y2
− −
) and in rats administered Y2-receptor mRNA antisense oligonucleotide.
RESULTS: The carriers having Pro7 in the preproNPY are markedly over-represented among type 2 diabetes patients with retinopathy compared to type 2 diabetes patients without retinopathy and to the population control. Neonatal exposure to hyperoxia resulted in development of retinal neovascularization that was prevented in Y2
− −
-mice, and significantly inhibited in rats treated with the Y2-receptor antisense oligonucleotide.
CONCLUSIONS: NPY and Y2-receptor play important roles in diabetic retinopathy and retinal neovascularization and are thus potential new targets for drug molecules for treatment of retinopathy.</abstract><cop>Basingstoke</cop><pub>Informa UK Ltd</pub><pmid>15181979</pmid><doi>10.1080/07853890410031236</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0785-3890 |
| ispartof | Annals of medicine (Helsinki), 2004, Vol.36 (3), p.232-240 |
| issn | 0785-3890 1365-2060 |
| language | eng |
| recordid | cdi_pascalfrancis_primary_15710234 |
| source | Taylor & Francis:Master (3349 titles); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Animals Biological and medical sciences Diabetes Mellitus, Type 1 - complications Diabetes Mellitus, Type 2 - complications Diabetic Retinopathy - etiology Female General aspects Humans Male Medical sciences Mice Middle Aged neuropeptide Y Neuropeptide Y - physiology Ophthalmology Rats Receptors, Neuropeptide Y - physiology Retinal Neovascularization - etiology Retinopathies retinopathy Y2-receptor |
| title | Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T20%3A56%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neuropeptide%20Y%20and%20Y2-receptor%20are%20involved%20in%20development%20of%20diabetic%20retinopathy%20and%20retinal%20neovascularization&rft.jtitle=Annals%20of%20medicine%20(Helsinki)&rft.au=Koulu,%20Markku&rft.date=2004&rft.volume=36&rft.issue=3&rft.spage=232&rft.epage=240&rft.pages=232-240&rft.issn=0785-3890&rft.eissn=1365-2060&rft_id=info:doi/10.1080/07853890410031236&rft_dat=%3Cproquest_pasca%3E71994703%3C/proquest_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71994703&rft_id=info:pmid/15181979&rfr_iscdi=true |